Statistical analyses
femoral condyle, enthesitis
REGRESSION, HAND ARTHRITIS, DISEASE CHARACTERISTIC, ENTHESITIS
Demographics and baseline disease characteristics were reported for patients who received ≥ 1 dose of study treatment. Descriptive statistics were generated for each endpoint by visit and treatment arm. Binary endpoints were analyzed using Cochran-Mantel–Haenszel statistics, with non-responder imputation for missing values. The 95% confidence intervals (CIs) were derived based on normal approximation. When compared with placebo, tofacitinib responses were defined as “greater,” “lower,” or “higher” if the corresponding 95% CIs did not overlap.Multivariate linear regression analyses based on backward selection criteria were conducted to determine the effects of baseline enthesitis location and severity on change from baseline in FACIT-F total score and arthritis pain (VAS) at months 3 and 6. Baseline covariates included were: the respective PRO being assessed; enthesitis in LEI locations (lateral epicondyle humerus [yes/no], medial femoral condyle [yes/no], Achilles tendon insertion [yes/no]); enthesitis severity based on LEI (0 vs 1, 2, or 3–6 affected sites); enthesitis in SPARCC locations (upper sites only [yes/no], lower sites only [yes/no], both upper and lower sites [yes/no]); and enthesitis severity based on SPARCC (0 vs 1–2, > 2– ≤ 5, or > 5 affected sites). In the pooled tofacitinib analysis, a variable for dose group (tofacitinib 5 mg BID vs 10 mg BID) was included in the model as a covariate. Statistical significance was defined as 